logo
  

Medtronic Guides Q4 Adj. EPS In Line With Estimates - Quick Facts

While reporting financial results for the third quarter on Tuesday, medical devices maker Medtronic plc. (MDT) provided its adjusted earnings and revenue growth guidance for the fourth quarter.

For the fourth quarter, the company now projects adjusted earnings in a range of $1.56 to $1.58 per share, which includes a neutral to slightly positive impact from foreign currency based on recent rates. The company also expects organic revenue growth of approximately 5.5 percent. Revenue would be negatively affected by approximately $185 million at current exchange rates

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.58 per share on revenue growth of 3.7 percent to $8.49 billion for the quarter. Analysts' estimates typically exclude special items.

"We are starting to see procedure volumes improve, and our outlook assumes continued recovery through March and April. By the time we exit the fourth quarter, we expect procedure volumes in most of our markets to be back to pre-COVID levels," said Karen Parkhill, Medtronic chief financial officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MTD Products Inc. is recalling 1,774 units of walk-behind self-propelled lawn mowers for potential risk of fire hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the lawn mower can leak fuel when it is stored in the upright (vertical) storage position to pose a fire hazard. Nike Inc. announced its plans to exit the Russian market completely following Russia's ongoing war against Ukraine, reports said. The sportswear major, with more than 100 stores in the country, had suspended operations there in March. Earlier in March, while suspending operations temporarily, the company had said its customers that it couldn't guarantee product shipments. The U.S. Food and Drug Administration unveiled its action plan to advance drug development for rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis or ALS, in five years. The FDA plans specific actions such as regulatory science initiatives, enhancements to existing programs and new policy initiatives for the purpose. It will use public-private partnerships...
Follow RTT